Deferasirox

Stumpf, Janice L.

doi:10.2146/ajhp060405

Cited by 54 publications

(60 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…I pazienti con anemie croniche -come i portatori di talassemia major o di anemia sideroblastica o di rare anemie congenite quali la falcemia o di sindromi mielodisplastichehanno necessità, per avere una migliore qualità di vita e aumentare la propria sopravvivenza, di regolari trasfusioni di sangue. Il sovraccarico di Fe che ne deriva, emosiderosi, comincia a dare segni istologici manifesti dopo che sono state trasfuse 10-20 unità di globuli rossi lavati, equivalenti a un apporto di circa 2-5 g di Fe elementare [2]. Dati recenti indicano che, paradossalmente, in queste condizioni risulta aumentato anche l'assorbimento intestinale del Fe [3].…”

Section: Il Carico DI Ferrounclassified

See 1 more Smart Citation

Deferasirox, an oral chelator in the treatment of iron overload

Portioli¹

2013

Ital J Med

View full text Add to dashboard Cite

Summary BACKGROUND Deferasirox is a once-daily oral iron chelator developed for treating iron overload complicating long-term transfusion therapy in patients with diseases such as beta-thalassemia and myelodysplastic syndromes. Iron overload can damage the liver, pancreas and the heart. Deferoxamine, the only other drug approved for iron chelation, can prevent these effects but requires parenteral administration. Deferasirox has been approved after a one-year, open-label trial in patients ≥ 2 years old with beta-thalassemia and transfusional emosiderosis randomized to once-daily oral 5, 10, 20, 30 mg/kg/day in comparison of subcutaneous deferoxamine 20-60 mg/mg/kg/day x 5/week. CONCLUSIONS Deferasirox 20-30 mg/kg/day produced reductions in liver iron concentration (LIC) similar to those with deferoxamine. Adverse effect of deferasirox (increases of serum creatinine and aminotransferases), including the gastrointestinal ones, are similar but more frequent than those occurring with deferoxamine. Information is lacking on the effects of deferasirox on cardiac iron and cardiac dysfunction which is the most serious complication of transfusional iron overload. KEY WORDSChelator Iron overload Liver iron concentration

show abstract

Section: Il Carico DI Ferrounclassified

“…Vi sono dati su soli 30 pazienti sopra i 65 anni, in gran parte affetti da sindrome mielodisplastica [2]. Il basso numero non permette di trarre alcuna conclusione.…”

Section: Anzianiunclassified

Deferasirox, an oral chelator in the treatment of iron overload

Portioli¹

2013

Ital J Med

View full text Add to dashboard Cite

show abstract

“…As the body has no physiological mechanism to excrete excess iron, repeated blood transfusions may result in iron overload [1].…”

Section: Introductionmentioning

confidence: 99%

“…To date, management of transfusional iron overload has consisted of chelation therapy with intravenous deferoxamine [1].…”

Section: Introductionmentioning

confidence: 99%

Gastric ulcer in a child treated with deferasirox

et al. 2010

View full text Add to dashboard Cite

show abstract

“…8 Deferasirox primarily undergoes glucoronidation by UGT1A1, with minimal oxidative metabolism through the cytochrome P-450 (CYP) system. 9 This leads to competitive inhibition for the enzyme and increased BU concentrations. Co-administration with deferasirox yielded a BU AUC that was 1.5 times higher than the level that was determined when we discontinued the drug (1868 vs 1173 mM min).…”

mentioning

confidence: 99%